# NIH Collaboratory Rethinking Clinical Trials®



EMBED: Pragmatic Trial of User-Centered Clinical Decision Support to Implement Emergency Department-Initiated Buprenorphine for Opioid Use Disorder

Ted Melnick MD, MHS


Gail D'Onofrio MD, MS




## The 24/7/365-day Option

To Fight the Opioid Crisis


#### **US Overdose Deaths**



#### **US Overdose Deaths**



#### **US Overdose Deaths**



#### The New Hork Times of the State of the New Hork Times of the State of

VOL. CLXVII .. No. 58.059

WASHINGTON — Republicans are struggling to make the \$1.5 trillion Trump tax cuts a winning issue with veces in the midterm congressional elections, but the cuts are helping the parry in another crucial way: unlocking tens of millions of dollars in cam-

closely aligned with Speaker Pau D. Ryan that is flooding the air

#### Trump Tax Cut Parishioners Didn't Suspect Him. Pays Dividends For the G.O.P. Then They Scrolled to Page 631.

Donors Who Receipe A small Catholic church in Pennsylvania reels after its Windfall Give Back



former priest is named in a report on sexual abuse.



That Treats Opioid Use as an Emergency

He Redefined U.N. in an Era

Of Turbulence



Fact-Checking the President 'Crazy Rich.' And Very Poor.

ethnic group in the United States, a cording to new data. PA States Take On Drug Prices

Stores View Them as Thieves Evangelist for the Sur

First Lady of Mystery

Live From New York, Still

TOP TRUMP AIDE GIVES MIJELLER COVETED DETAILS

ASSISTANCE IS UNUSUAL

White House Counsel's Strategy Evolves Into Survival Tactic

w a Democracy; Turkey En braced an Autocrat

It's Not Just Rubik's Anymore

### Front Page News

#### Sunday, August 19, 2018

#### An E.R. That Treats Opioid Use as an Emergency

#### By ABBY GOODNOUGH

OAKLAND, Calif. - Every year, thousands of people addicted to opioids show up at hospital emergency rooms in withdrawal so agonizing it leaves them moaning and writhing on the floor.

#### THE TREATMENT GAP

Help on Demand

Usually, they're given medicines that help with vomiting or diarrhea and sent on their way, maybe with a few numbers to call about treatment.

When Rhonda Hauswirth arrived at the Highland Hospital E.R. here, retching and shaking violently after a day and a half without heroin, something very different happened. She was offered a dose of buprenorphine on the spot. One of three medications approved in the United States to treat opioid addiction, it works by easing withdrawal symptoms and cravings. The tablet dissolved under her tongue while she slumped in a plastic chair, her long red hair obscuring her ashen face.

Soon, the shakes stopped. "I could focus a little more. I could see straight," said Ms. Hauswirth, 40, "I'd never heard of anyone going to an emergency room to do



BRIAN L. FRANK FOR THE NEW YORK TIMES

Dr. Andrew Herring giving the withdrawal drug buprenorphine to a homeless patient at Highland Hospital in Oakland, Calif.

Highland, a clattering big-city hospital where security wands constantly beep as new patients get scanned for weapons, is among a small group of institutions that have started initiating opioid addiction treatment in the E.R. Their aim is to plug a gaping hole in a medical system that consistently fails to provide treatment on demand, or any evidencebased treatment at all, even as more than two million Americans suffer from opioid addiction. According to the latest estimates. overdoses involving opioids killed

nearly 50,000 people last year.

By providing buprenorphine around the clock to people in crisis - people who may never otherwise seek medical care - these E.R.s are doing their best to ensure a rare opportunity isn't lost.

"With a single E.R. visit we can provide 24 to 48 hours of withdrawal suppression, as well as suppression of cravings," said Dr. Andrew Herring, an emergency medicine specialist at Highland who runs the buprenorphine program. "It can be this revelatory

Continued on Page 20

### Why Focus on the ED?



### Because that's where the patients are!



**July 2016 - September 2017** 

30%

Visits for Opioid Overdose

MMWR, March 9, 2018

# EDs and Emergency Physicians can...

- Identify patients with opioid use disorder
- Initiate treatment
  - buprenorphine
  - overdose education & naloxone distribution
- Link to continued opioid agonist treatment
   & preventive services

### What is the Evidence?

## A Randomized Trial of ED-Initiated Interventions for Opioid Dependence

Research

D'Onofrio, G., O'Connor, P.G., Pantalon, M.V., Chawarski, M.C., Busch, S.H., Owens, P.H., Bernstein, S.L. and Fiellin, D.A.

Original Investigation

Emergency Department-Initiated Buprenorphine/Naloxone
Treatment for Opioid Dependence
A Randomized Clinical Trial

Gail D'Onofrio, MD, MS; Patrick G. O'Connor, MD, MPH; Michael V. Pantalon, PhD; Marek C. Chawarski, PhD; Susan H. Busch, PhD; Patricia H. Owens, MS; Steven L. Bernstein, MD; David A, Fiellin, MD

IMPORTANCE Opioid-dependent patients often use the emergency department (ED) for medical care.


**OBJECTIVE** To test the efficacy of 3 interventions for opioid dependence: (1) screening and referral to treatment (referral); (2) screening, brief intervention, and facilitated referral to community-based treatment services (brief intervention); and (3) screening, brief intervention, ED-initiated treatment with buprenorphine/naloxone, and referral to primary care for 10-week follow-up (buprenorphine).

DESIGN, SETTING, AND PARTICIPANTS A randomized clinical trial involving 329 opioid-dependent patients who were treated at an urban teaching hospital ED from April 7, 2009, through June 25, 2013.


INTERVENTIONS After screening, 104 patients were randomized to the referral group, 111 to




### MAT: 2x More Likely to be Engaged in **Addiction Treatment at 30 Days**



### **Medication for Opioid Use Disorder**




Kakko. Lancet 2003



LaRochelle. Annals of IM 2018



### NIDA Clinical Trials Network: Opioid Use Disorder in the ED Project ED Health (CTN-0069)



0079 Clinical Trials Network: Initiating Extended Release Buprenorphine for OUD in Low Resourced, High Intensity EDs








EMBED: Pragmatic trial of user-centered clinical decision support to implement
 EMergency department-initiated
 Buprenorphin for opioid use Disorder

UG3 AT009851-01 UG3-UH3





### **Diffusion of Innovations**




Rogers. Diffusion of Innovations 1962

Gladwell. Tipping Point 2000

Dearing & Cox. Health Affairs Feb 2018

### **Diffusion of Innovations**



- Rogers. Diffusion of Innovations 1962
- Gladwell. Tipping Point 2000
- Dearing & Cox. Health Affairs Feb 2018

### **Background: HIT**


- Poor health IT (HIT) usability is major source of frustration with clinicians
- Electronic health record (EHR) usability is a fundamental barrier to implementation of evidence-based medicine
- IT should be designed to meet user needs
- User-centered design
  - streamline workflows
  - address barriers to adoption
  - embed ED-initiated BUP into routine ED care
  - to optimize adoption, dissemination, implementation, and scalability





### Aims: UG3

 UG3 Aim 1. Develop a pragmatic, user-centered CDS for EDinitiated BUP and referral for MAT in ED patients with OUD which will automatically identify and facilitate management of potentially eligible patients.

UG3 Aim 2. Establish the infrastructure for the proposed trial.







#### **UH3 Aims**

- 1. Compare the effectiveness of user-centered CDS for BUP to usual care on outcomes in ED patients with OUD.
- 2. Disseminate the EMBED intervention nationally

### Teams and People

#### **MPI**

- Ted Melnick, MD, MHS
- Gail D'Onofrio, MD, MS

#### Design

- Matt Maleska
- Jessica Ray, PhD

#### **Technology**

- Allen Hsiao, MD
- Yauheni Solad, MD, MHS
- Hyung Paek, MD, MSEE
- Cynthia Brandt, MD, MPH

#### **Data coordination**

- Jim Dziura, PhD, MPH
- Lilly Katsovich, MBA
- Charles Lu

#### **Project Coordinator**

Shara Martel MPH, MS


#### **External collaborators**

- UNC
  - Tim Platts-Mills, MD, MSc
  - Mehul Patel, PhD
- Mayo
  - Molly Jeffery, PhD
- UAB
  - Erik Hess, MD, MSc
  - Jim Galbraith, MD
- Also: UC Davis
  - Josh Elder MD, MPH, MHS
- Colorado
  - Jason Hoppe, DO

#### Within each system

- Medical director
  - Clinical champions
  - IT leaders
  - MAT site contacts

#### **EMBED TIMELINE**



### **Sites**

pilot sites

confirmed trial sites

potential trial sites





ΤН

MS





ĤΖ

ΝM




THE UNIVERSITY OF ALABAMA

### **User-centered design progress**

- Currently 25-30 minute workflow for an addiction counselor
  - Diagnostic criteria
  - Withdrawal assessment
  - Readiness for treatment
  - Treatment initiation
  - Referral (detailed form completed and faxed to referral center)
- Need to embed this in ED clinician busy, dynamic, interruptive workflow
- Goal to identify, treat, and refer in 2-5 minutes while
  - Minimize interruptions & additional cognitive load
  - Allow flexibility for initiation of tool, which parts to use, clinicians training for BUP use, novice-to-expert tool use
  - 30 mouse clicks down to as little as 1

### **Buprenorphine Integration Pathway**




#### **ED-Initiated Buprenorphine**

Diagnosis of Moderate to Severe Opioid Use Disorder

#### Assess for opioid type and last use

Patients taking methadone may have withdrawal reactions to buprenorphine up to 72 hours after last use Consider consultation before starting buprenorphine in these patients



#### Notes:

- starting with 8 mg buprenorphine or buprenorphine/naloxone SL
- \*\* Patient remains in moderate withdrawal may consider adding additional 4mg and observation for 60 minutes
- programs within 24-72 hours whenever possible
- All patients should be educated regarding dangers of benzodiazepine and alcohol co-use

Ancillary medication treatments with buprenorphine induction are not needed

16mg dosing for each day until appointment for ongoing treatment

Consider return to the ED for (72-hour rule) Referral for ongoing treatment



#### Buprenorphine (BUP) Initiation

Do you have a waiver to prescribe Buprenorphine?

No



Yes

#### **Buprenorphine Treatment Options**


TEXT 555-555-5555


WWW.WEBADDRESSHERE.COM

QR CODE

#### Select from one of the four treatment options below

	Care Pathway #1	Care Pathway #2	Care Pathway #3	Care Pathway #4	Decision Support
	Exit / No BUP	Hold in ED	Start 4 mg BUP (2x)	Start 8 mg BUP	Use these optional tools in any order to help you decide
					$\downarrow$
Does the patient have Opioid Use Disorder?	No X (<3 DSM Criteria)	Yes (>/= 3 DSM Criteria)	Yes (>/= 3 DSM Criteria)	Yes (>/= 3 DSM Criteria)	Diagnose OUD using DSM tool
How severe is the patient's withdrawal?	None-to-Mild  < 8  DO NOT give if intoxicated	None-to-Mild  < 8  DO NOT give if intoxicated	Mild-to-Moderate 8 - 13	Moderate-to-Severe	Assess withdrawal using COWS tool
Is the patient ready to start treatment?	No No	YES	YES	YES	Motivate Readiness using interview tool
	Select #1	Select #2	Select #3	Select #4	





#### Clinical Opiate Withdrawal Scale (COWS)

For each item, select the appropriate description of the patient's signs or symptoms (points per symptom) Score 81 - 100 (t) 101 - 120 (2) > 120 (4) Resting Pulse Rate (0) woled to 08 Frequent shifting of limbs (3) Unable to sit still (5) Restlessness Able to sit still (0) Some difficulty sitting still (1) 5 Anxiety or irritability None (0) Increasing amounts (1) Obviously irritable/anxious (2) Too difficult to participate (4) 2 Yawning 1 or 2 times/assessment (1) 3 or 4 times/assessment (2) Several times/minute (4) No yawning (0) Pupil Size Possibly larger (1) Normal (0) Moderately dilated (2) Only rim of iris visible (5) Constant running/ Stuffiness/moist eyes (1) Runny nose or tearing Nose running/tearing (2) Not present (0) tears streaming (4) Gross tremor/twitching (4) Tremor Slight tremor observable (2) No tremor (0) Felt - not observed (1) Sweating No report (0) Subjective report (1) Flushed / observable (2) Beads of sweat (3) Streaming down face (4) 3 Gooseflesh skin Prominent piloerrection (5) Skin is smooth (0) Piloerection/hairs standing (3) 3 Bone or joint pain Not present (0) Mild discomfort (1) Severe aching (2) Unable to sit due to pain (4) 2 Gl upset Nausea or loose stool (2) Vomiting or diarrhea (5) Multiple episodes (5) No symptoms (0) Stomach cramps (1) 8 - 13 25 Return to treatment options Moderate-to-Severe

#### A Guide for Patients Beginning Buprenorphine Treatment at Home

#### Before you begin you want to feel very sick from your withdrawal symptoms

It should be at least ...

- · 12 hours since you used heroin/fentanyl
- · 12 hours since snorted pain pills (Oxycontin)
- . 16 hours since you swallowed pain pills
- · 48-72 hours since you used methadone

You should feel at least three of these symptoms ...

- Restlessness
- · Heavy yawning
- · Enlarged pupils
- · Runny nose
- · Body aches
- · Tremors/twitching
- · Chills or sweating
- Anxious or irritable
- Goose pimples
- Stomach cramps, nausea, vomiting or diarrhea

#### Once you are ready, follow these instructions to start the medication

#### DAY 1:

#### 8-12mg of buprenorphine

Most people feel better the first day after 8-12mg. (Dosing depends on how early on the first day you started)

# Take the first dose Wait 45 minutes 45 minutes

- Put the tablet or strip under your tongue
- Keep it there until fully dissolved (about 15 min.)
- . Do NOT eat or drink at this time
- Do NOT swallow the medicine





#### DAY 2: 16mg of buprenorphine

#### Take one 16mg dose

Most people feel better with a 16mg dose



Repeat this dose until your next follow-up appointment

If you develop worsening symptoms while starting buprenorphine before your scheduled outpatient appointment return to the emergency department

# Thank You



#### **Websites**

https://drugabuse.gov/ed-buprenorphine

https://medicine.yale.edu/edbup/